Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Solomon

Showing results (1081-1090 of 1,873) with videos related to

Pageof 188
Sort By:
Circulation. Heart Failure|May 24, 2011
Dyssynchrony, contractile function, and response to cardiac resynchronization therapyDorit Knappe, Anne-Catherine Pouleur, Amil M Shah, et al.
JACC. Heart Failure|April 12, 2014
Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction)Eldrin F Lewis, Yanhong Li, Marc A Pfeffer, et al.
ESC Heart Failure|March 12, 2021
Sex differences in congestive markers in patients hospitalized for acute heart failureCaroline Espersen, Ross T Campbell, Brian Claggett, et al.
Journal of the American Heart Association|February 19, 2025
In-Hospital or Out-of-Hospital Initiation of Sacubitril/Valsartan Versus Valsartan in Patients With Mildly Reduced or Preserved Ejection Fraction After A Worsening Heart Failure Event: The PARAGLIDE-HF TrialNina Nouhravesh, Derek Cyr, Adrian F Hernandez, et al.
JAMA Cardiology|August 30, 2024
Effects of Sacubitril/Valsartan on All-Cause Hospitalizations in Heart Failure: Post Hoc Analysis of the PARADIGM-HF and PARAGON-HF Randomized Clinical TrialsHenri Lu, Brian L Claggett, Milton Packer, et al.
JACC. Heart Failure|November 15, 2020
Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection FractionIleana L Piña, Alexander Camacho, Nasrien E Ibrahim, et al.
Journal of the American College of Cardiology|November 13, 2007
Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM ProgramAkshay S Desai, Karl Swedberg, John J V McMurray, et al.
Circulation|November 21, 2007
Influence of albuminuria on cardiovascular risk in patients with stable coronary artery diseaseScott D Solomon, Julie Lin, Caren G Solomon, et al.
Circulation. Heart Failure|January 26, 2018
Hyporesponsiveness to Darbepoetin Alfa in Patients With Heart Failure and Anemia in the RED-HF Study (Reduction of Events by Darbepoetin Alfa in Heart Failure): Clinical and Prognostic AssociationsPeter van der Meer, Niels Grote Beverborg, Marc A Pfeffer, et al.
Circulation. Heart Failure|May 17, 2021
Association Between Angiotensin Receptor-Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection FractionSean P Murphy, Margaret F Prescott, Alan S Maisel, et al.
Pageof 188

Showing results (1081-1090 of 1,873) with videos related to

Sort By:
Pageof 188
Circulation. Heart Failure|May 24, 2011
Dyssynchrony, contractile function, and response to cardiac resynchronization therapyDorit Knappe, Anne-Catherine Pouleur, Amil M Shah, et al.
JACC. Heart Failure|April 12, 2014
Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction)Eldrin F Lewis, Yanhong Li, Marc A Pfeffer, et al.
ESC Heart Failure|March 12, 2021
Sex differences in congestive markers in patients hospitalized for acute heart failureCaroline Espersen, Ross T Campbell, Brian Claggett, et al.
Journal of the American Heart Association|February 19, 2025
In-Hospital or Out-of-Hospital Initiation of Sacubitril/Valsartan Versus Valsartan in Patients With Mildly Reduced or Preserved Ejection Fraction After A Worsening Heart Failure Event: The PARAGLIDE-HF TrialNina Nouhravesh, Derek Cyr, Adrian F Hernandez, et al.
JAMA Cardiology|August 30, 2024
Effects of Sacubitril/Valsartan on All-Cause Hospitalizations in Heart Failure: Post Hoc Analysis of the PARADIGM-HF and PARAGON-HF Randomized Clinical TrialsHenri Lu, Brian L Claggett, Milton Packer, et al.
JACC. Heart Failure|November 15, 2020
Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection FractionIleana L Piña, Alexander Camacho, Nasrien E Ibrahim, et al.
Journal of the American College of Cardiology|November 13, 2007
Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM ProgramAkshay S Desai, Karl Swedberg, John J V McMurray, et al.
Circulation|November 21, 2007
Influence of albuminuria on cardiovascular risk in patients with stable coronary artery diseaseScott D Solomon, Julie Lin, Caren G Solomon, et al.
Circulation. Heart Failure|January 26, 2018
Hyporesponsiveness to Darbepoetin Alfa in Patients With Heart Failure and Anemia in the RED-HF Study (Reduction of Events by Darbepoetin Alfa in Heart Failure): Clinical and Prognostic AssociationsPeter van der Meer, Niels Grote Beverborg, Marc A Pfeffer, et al.
Circulation. Heart Failure|May 17, 2021
Association Between Angiotensin Receptor-Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection FractionSean P Murphy, Margaret F Prescott, Alan S Maisel, et al.
Pageof 188